Clinical Trial Update: Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa [Phase 3]

View source ↗

Summary

Phase 3 trial update for GSK's malaria vaccine candidate 257049 in infants and children in Africa; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Malaria vaccine 257049

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria | Phase 3 | Status: COMPLETED | Results posted: 2019-10-09